Superluminal Medicines Inc.

Sr. Scientist, Discovery Biology

Superluminal Medicines Inc.  •  Boston, MA (Onsite)  •  5 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

About Superluminal Medicines:

Superluminal Medicines is a generative biology and chemistry company revolutionizing the speed and accuracy of how small molecule medicines are created. The Company’s platform aims to create candidate-ready compounds with unprecedented speed using a combination of deep biology, computational and medicinal chemistry, machine learning, and proprietary big data infrastructure. We are expanding the team of talented scientists who seek to build the future of small molecule drug discovery with creativity and innovation.

About the Role:

We are seeking a highly motivated and experienced drug discovery biologist join our growing Discovery

Biology team. The successful candidate brings significant hands-on expertise in cell-based assay

development and enablement to drive early drug discovery programs. The candidate will lead from the bench

and contribute to biology strategy and execution across Superluminal programs.

Key Responsibilities:

  • This role is hands-on and wet lab-focused to drive programs from hit finding through all phases of early

discovery.

  • Independently design, develop and execute a broad array of cell-based assays to interrogate GPCR

function and signaling.

  • Generate, analyze, document, and upload experimental and routine screening data to company

databases in a timely and accurate manner.

  • Collaborate cross-functionally with computational, chemistry and protein science colleagues to

conceptualize, design, and execute novel screening assays.

  • Regularly communicate findings with program teams and present at project & company-wide meetings.
  • Ensure compliance with established laboratory practices, SOPs, and company policies, including both

wet lab and electronic data management requirements.

Minimum Qualifications

  • Ph.D. in Biology or a related life sciences field, with 5 or more years of relevant industry experience.
  • Demonstrated hands-on experience developing, executing, and interpreting cell-based assays using

multiple assay formats and platforms, including functional assays, target engagement assays, kinetic

assays, plate-based assays, flow cytometry, and high-content imaging.

  • Small molecule drug discovery experience required.
  • Demonstrated problem-solving skills and ability to develop innovative solutions to complex challenges.
  • Ability to work onsite 5 days a week required.

Preferred Qualifications:

  • Experience with GPCR biology is highly desired.
  • Experience with assay automation, high-throughput screening, or laboratory robotics is a plus.
  • Management experience is a plus.

Benefits:

Superluminal offers a comprehensive benefits package that fully covers employees’ annual deductibles and monthly premiums for medical, dental, and vision insurance. The package also includes a 401(k) match program, a Massachusetts transportation subsidy, equity, unlimited paid time off, and both disability and life insurance.

Equal Opportunity Statement:

Superluminal Medicines is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.

Superluminal Medicines Inc.

About Superluminal Medicines Inc.

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.

Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.

With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

Industry
Biotech & Life Sciences
Company Size
11-50 employees
Headquarters
Boston, Massachusetts
Year Founded
Unknown
Social Media